Famotidine and Antacids for Treatment of Dyspepsia

Description

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Conditions

Dyspepsia, GERD, Acid Reflux

Study Overview

Study Details

Study overview

The aim of this study is to compare intravenous famotidine, an H2 receptor antagonist, and Maalox/ Mylanta, an oral antacid, in treatment of dyspepsia in the emergency department. The goal of this study is to reduce patients' pain based on the verbal numerical pain scale. The anticipated outcome is for pain levels in both groups to decrease. It is expected that antacids will improve symptoms more quickly and to a greater degree within an hour of taking medication based on the results of similar studies.

Comparing Intravenous Famotidine and Oral Antacids in the Treatment of Dyspepsia in the Emergency Department

Famotidine and Antacids for Treatment of Dyspepsia

Condition
Dyspepsia
Intervention / Treatment

-

Contacts and Locations

Stony Brook

Stony Brook University Hospital, Stony Brook, New York, United States, 11794

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Subject Age ≥ 18 years of age
  • 2. Patient diagnosed with dyspepsia
  • 3. Present at the ED with upper abdominal pain score of at least 3
  • 1. Hypersensitivity to an ingredient in Maalox/ Mylanta or Famotidine
  • 2. Moderate to Severe Renal Insufficiency (precaution)
  • 3. Kidney Failure
  • 4. Pregnant or Nursing
  • 5. Verbal pain score less than 3
  • 6. Inability to tolerate oral medications
  • 7. Bowel Obstruction
  • 8. Proton pump inhibitor within 2 hours of study treatment

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Stony Brook University,

Study Record Dates

2025-12